CiToxLAB and KaLy-Cell join forces to offer in vitro and ex vivo testing for hepatotoxicity and metabolism

 

CiToxLAB_Quadri_20142     KaLy-Cell

 


Evreux and Plobsheim, France, June 15, 2017
– CiToxLAB, a leading CRO in the field of non-clinical research, announces today its partnership with KaLy-Cell, a company specialized in the evaluation of hepatic toxicity and in vitro and ex vivo metabolism tests.

 

This partnership will allow both companies to meet the growing demand from clients in the pharmaceutical, biotech and chemical industries for predictive tests to evaluate hepatotoxicity and to perform metabolism studies during product development. 

Press release download : CiToxLAB and KaLy-Cell join forces to offer in vitro and ex vivo testing for hepatotoxicity and metabolism


 

 

 

 

DILI-SCREEN_1

 

Since March 2017, KaLy-Cell is involved, together with Karolinska institutet an the Eurostars’ Project E! 11034 Cryosphere: 3D co-cultures of human parenchymal and non prenchymal cells  from the same liver; Prediction of drug-induced liver injury.

 

 


etb

 

Since October 2015, KaLy-Cell is involved with the German SME HepaCult in the collaborative Eurotransbio Project HepaCells: “Supply of high quality non-parenchymal hepatic cells to improve the prediction of hepatotoxicity assays”.

 

 

 


Since March 2012, KaLy-Cell is involved in the collaborative project MIP-DILI: “Mechanism-based Improved systems for the Prediction of Drug Induced Liver Injury”, a project funded by the Innovative Medicines Initiative (IMI) and EFPIA.

 

 

Press release download : PRESS RELEASE IMI LAUNCHES SEVEN NEW PROJECTS TO BOOST DRUG DEVELOPMENT 

 

For more information

Contact us

Register for our
HepatAlert notifications
for fresh or cryoplateable hepatocytes.

Request a quote!

Contact us

We look forward to
helping you find the best
solution for your
compound development
program.